Cargando…
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major the...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731024/ https://www.ncbi.nlm.nih.gov/pubmed/19707284 |
_version_ | 1782170921841197056 |
---|---|
author | Khoo, Joan Rayner, Christopher K Jones, Karen L Horowitz, Michael |
author_facet | Khoo, Joan Rayner, Christopher K Jones, Karen L Horowitz, Michael |
author_sort | Khoo, Joan |
collection | PubMed |
description | The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term. |
format | Text |
id | pubmed-2731024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27310242009-08-25 Incretin-based therapies: new treatments for type 2 diabetes in the new millennium Khoo, Joan Rayner, Christopher K Jones, Karen L Horowitz, Michael Ther Clin Risk Manag Review The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term. Dove Medical Press 2009 2009-08-20 /pmc/articles/PMC2731024/ /pubmed/19707284 Text en © 2009 Khoo et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Khoo, Joan Rayner, Christopher K Jones, Karen L Horowitz, Michael Incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
title | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
title_full | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
title_fullStr | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
title_full_unstemmed | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
title_short | Incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
title_sort | incretin-based therapies: new treatments for type 2 diabetes in the new millennium |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731024/ https://www.ncbi.nlm.nih.gov/pubmed/19707284 |
work_keys_str_mv | AT khoojoan incretinbasedtherapiesnewtreatmentsfortype2diabetesinthenewmillennium AT raynerchristopherk incretinbasedtherapiesnewtreatmentsfortype2diabetesinthenewmillennium AT joneskarenl incretinbasedtherapiesnewtreatmentsfortype2diabetesinthenewmillennium AT horowitzmichael incretinbasedtherapiesnewtreatmentsfortype2diabetesinthenewmillennium |